This novel family of peptides share many common features with the chemokine superfamily, such as their small size 8 kDa, receptors [G-protein coupled receptors GPCRs], signaling Keywords
Trang 1Cytokine properties of prokineticins
Justin Monnier and Michel Samson
INSERM U620, Universite´ de Rennes 1, IFR 140, Rennes Cedex, France
Introduction
Prokineticin 1 (PROK1) and prokineticin 2 (PROK2),
otherwise known as endocrine gland vascular
endo-thelial factor (EG-VEGF) and Bombina variegata 8
(Bv8), respectively, are a novel family of peptides that
are highly conserved across species Indeed,
prokineti-cin-like peptides are present in invertebrates (crayfish,
shrimp), vertebrates (black mamba snake, frogs, trout,
fugu) and mammals (rodents, bull, humans) [1,2] One
of the first biological activities reported was the ability
of the amphibian orthologue of PROK2 (Bv8) to elicit
hyperalgesia in rats and to induce gastrointestinal
motility of guinea-pig ileum [3] Subsequently, the
human recombinant form of prokineticins was shown
to have similar gastrointestinal motility activities in
guinea-pigs [3,4] Both studies confirm that
prokinetic-ins are structurally conserved across species and show
highly conserved bioactivities Not long after, it was
demonstrated that PROK1 and PROK2 also had potent angiogenic properties independent of vascular endothelial growth factor [5] Since then, numerous other biological activities have been associated with prokineticins, such as angiogenesis, neurogenesis, ingestive behaviours and hormone release, gastrointes-tinal motility, circadian rhythms, pain sensation, and blood cell function and development [2,6–11] Further-more, the most elegant demonstration of the implica-tion of prokineticins in a human disease has been brought by the identification that different point muta-tions in the genes encoding PROK2 or the Gprotein-coupled prokineticin receptor-2 (PROKR2) can lead to Kallmann syndrome [6,12,13]
This review aimed to retrace all the cytokine proper-ties of prokineticins This novel family of peptides share many common features with the chemokine superfamily, such as their small size (8 kDa), receptors [G-protein coupled receptors (GPCRs)], signaling
Keywords
chemokine; chemokine receptor; cytokine;
dendritic cells; GPCR; innate immunity;
macrophages; myeloid cell; prokineticin;
prokineticin receptor
Correspondence
M Samson, INSERM U620, Universite´ de
Rennes 1, 2 avenue du Prof Le´on Bernard,
35043 Rennes cedex, France
Fax: (+33) 02 23 23 47 94
Tel: (+33) 02 23 23 48 06
E-mail: michel.samson@univ-rennes1.fr
(Received 26 March 2008, revised 20 May
2008, accepted 17 June 2008)
doi:10.1111/j.1742-4658.2008.06559.x
Prokineticins are a novel family of secreted peptides with diverse regulatory roles, one of which is their capacity to modulate immunity in humans and
in other species Prokineticins are small peptides of 8 kDa that mediate their biological activities by signaling through two homologous G-protein-coupled receptors (prokineticin receptor 1 and prokineticin receptor 2) This family of peptides is characterized by a completely conserved N-termi-nal hexapeptide crucial for their bioactivities and a unique structural motif comprising five disulfide bonds Prokineticins and their receptors are highly expressed in bone marrow, in peripheral circulating leukocytes, in inflamed tissues and in resident organ immune cells Their structure, size, signaling and biological activities are reminiscent of the chemokine superfamily
In this review, emphasis is placed on the properties of prokineticins as cytokines and their role in the immune system
Abbreviations
Bv8, Bombina variegata 8; GM-CSF, granulocyte–macrophage colony-stimulating growth factor; GPCR, G-protein coupled receptor; IL, interleukin; LPS, lipopolysaccharide; MIP, macrophage inflammatory protein; PROK1, prokineticin 1; PROK2, prokineticin 2; PROKR1, prokineticin receptor 1; PROKR2, prokineticin receptor 2; TNF-a, tumor necrosis factor-a.
Trang 2mechanisms, and chemotactic and immunomodulatory
activities Therefore, in the present study we first
described the gene, protein structure, signaling and
biochemical properties of prokineticins, which showed
similarity to some cytokines, notably chemokines and
defensins Second, we overviewed the cellular source of
both prokineticins and their receptors throughout
immune cells Finally, their numerous activities as
cytokines were overviewed
Comparison of gene and protein
struc-ture of prokineticins and prokineticin
receptors with chemokines
Ligands PROK1 and PROK2
The gene that encodes PROK1 (86 amino acids) is
located on chromosome 1p21 It is composed of three
exons, with no known alternative splicing product [14]
The PROK2 gene maps to chromosome 3p21.1 and it
is composed of four exons, which gives rise to two
mature proteins: PROK2 (81 amino acids) (exons 1, 2
and 4) and a splice variant with a 21-amino acid insert
called PROK2L (102 amino acids) (exons 1, 2, 3 and
4) PROK1 and PROK2 share approximately 44%
amino acid identity [9] In contrast to PROK1 and
PROK2, which are located on different chromosomes,
the genes encoding chemokines are often on the same
chromosome and their loci are physically very close
(i.e CXC chemokines are almost all located on
chro-mosome 4q21) [15] Furthermore, the genetic loci of
both prokineticins are not physically near any cytokine
family genes and it thus appears unlikely that both
prokineticin and cytokine genes could be involved in
translocation phenomenon pathologies
After signal peptide processing, the secreted peptide
contains distinctive structural motifs that are highly
conserved across species One such motif is the
N-termi-nal AVIT sequence and another comprises 10 conserved
cysteine residues [1,9] This N-terminal AVIT sequence
is essential for the correct binding of receptors [16]
However, it has not yet been identified if prokineticins
can undergo in vivo proteolytic cleavage by extracellular
proteases As observed with chemokines, the N-terminal
domain is also essential for receptor binding because
cleavage of peptides from the N terminus by
extra-cellular proteases regulates chemokine bioavailability by
either increasing or decreasing the biological activity of
the chemokine [17] Furthermore, prokineticins are
highly basic Indeed, PROK1 binds with high affinity to
heparin–sepharose, and PROK2 and PROK2L are
predicted to be highly basic with a pI of 8.85 and a pI
of 10.68, respectively Thus, prokineticin activity may
also be regulated through the binding of extracellular components, such as sulphate proteoglycans [14] Inter-estingly, the members of the chemokine family are also highly basic, and their bioactivity is tightly regulated through interactions with heparin sulfates of the extra-cellular matrix [18] Chemokines contain four to six cys-teine residues, and this is a marked structural difference from prokineticins, which contain 10 cysteine residues The 10 cysteine residues form five disulphide bonds that confer a compact structure on the molecule, with N-and C-termini present on the surface One side of the roughly ellipsoid protein has a positive net charge, whereas the opposite side is hydrophobic [2]
We performed a phylogenic study in order to com-pare the degree of similarity among prokineticins, chemokines and defensins, (which, similarly to proki-neticins, also contain a high number of cysteine resi-dues) [19–22] Interestingly, the results of the pylogenic study revealed a higher similarity of amino acid sequence between defensins and prokineticins than with chemokines (Fig 1A)
Receptors PROKR1 and PROKR2 There are two prokineticin receptors, named prokineti-cin receptor 1 (PROKR1) and prokinetiprokineti-cin receptor 2 (PROKR2); they are two closely related seven-trans-membrane GPCRs that belong to the family of the neuropeptide Y receptor PROKR1 is located on chromosome 2p13.1 and PROKR2 is located on chro-mosome 20p12.3 No genes encoding cytokine receptors are located near prokineticin receptors Interestingly, similarly to their ligands, both receptors are on different chromosomes, and this contrasts with chemokine recep-tors that are often located on the same chromosome, such as CCR1, CCR2, CCR3, CCR4, CCR5 that are located very closely on chromosome 3p21.3-24 [23] Furthermore, all chemokine receptors are also
G protein seven-transmembrane-coupled receptors, which is another common element shared between chemokines and prokineticins However, they diverge
in sequence with PROKRs, as can be seen in the phylogenetic tree (Fig 1B), where the closest related chemokine receptor to PROKRs is XCR1
Expression and regulation of prokineticins and prokineticin receptors in immune cells
Ligand expression Several studies have reported a differential expression
of PROK1 and PROK2 within immune cells Indeed,
Trang 3LeCoulter et al showed, in 2004, that within human
peripheral leukocytes only PROK2 was detected, and
the highest expression was observed in bone marrow,
neutrophils, dendritic cells and monocytes [24] In
con-trast, another study reported a significant expression
of PROK1 in CD14+ cells, T cells and B cells;
how-ever, PROK2 expression was not evaluated [24] We
measured the expression of PROK1 and PROK2 in
fresh human monocytes obtained from 10 different healthy donors and our results consistently showed very high expression of PROK2 but undetectable expression of PROK1 (data not shown) Furthermore,
we recently showed that the resident macrophage population of human liver (called Kupffer cells) was the specific source of PROK2 in liver, whereas PROK1 was weakly expressed [25]
Prokineticins have been associated differentially with inflammatory and immune tissues Transcript analysis showed higher expression of PROK1 in rheumatoid arthritis synoviocytes and in Crohn’s disease compared with normal tissue [24] In situ localization in appendi-citis and tonsillitis samples revealed high expression of PROK2 in infiltrating neutrophils [26] Interestingly, PROK1 transcripts were detected in tumor-infiltrating
T lymphocytes in ovarian carcinoma [27]
In other species, immunohistochemical staining revealed that PROK1 was expressed in macrophages
of bovine corpus luteum regression and follicular atresia [27,28] In BALB⁄ c mice, peritoneal macro-phages were shown to express only PROK2 [29] How-ever, in C57BL6 mice, PROK1 was shown to bind monocyte⁄ macrophage cells in the spleen [24] Recently, Shojaei et al [30] demonstrated in BALB⁄ c nude mice implanted with several tumor cell lines that the bone marrow mononuclear cells subset enriched in PROK2 were CD11b+GR1+ cells, consisting mainly
of macrophage and neutrophil lineage cells These results might reflect intraspecies variations
Taken together, from the literature and from our own results it seems that PROK2 is preferentially expressed by cells from the monocyte–granulocyte line-age and PROK1 seems to be less specifically expressed
by immune cells
Receptor expression PROKR2 has been shown to be expressed more highly than PROKR1, in particular in CD8 cells, monocytes and neutrophils [26] In contrast, Dorsch et al reported a low expression of PROKR2 in monocytes, but a substantial expression of both receptors in B cells [24] Recently, we studied the expression of PRO-KR1 and PROKR2 in fresh human monocytes from
10 different donors at the protein level using flow cytometry and we observed that both receptors were expressed on the monocyte surface (J Monnier,
V Quillien, C Piquet-Pellorce, C Leberre, L Preisser,
H Gascan & M Samson, unpublished data) In addi-tion, we showed that in liver hepatic cells both PRO-KR1 and PROKR2 mRNA were only expressed at high levels by Kupffer cells [25] In mice peritoneal
A
B
CCR6 0.7
0.8
CXCL8 CXCL9
CXCL11 CXCL10 CXCL3
CXCL1 CXCL2 CCL4
CCL5CCL18 CCL3 CCL13CCL8
CCL7 CCL2XCL2 XCL1 CX3CL1
PROK1 PROK2 PROK2L DEFb1 DEFa4DEFa3 DEFa1 DEFb4
DEFb2
CXCR6
CXCR4 CXCR5 CXCR3
CCR10 CXCR2
CXCR1 CCR9 CCR7 CCR4 CCR5 CCR2 CCR3 CCR1 CCR8 CX3CR1 CXCR7 XCR1
PKR2 PKR1
Fig 1 Phylogenic study comparing prokineticins with chemokines
and defensins Sequence alignment was performed using CLUSTALW
[22]; phylogeny was performed using the approximate
likelihood-ratio test for branches, PHYML [20,21], visualization of phylogenic
trees was performed using TREEDYN [19] (A) Dendrogram
represent-ing amino acid sequence similarity among prokineticins,
chemo-kines and defensins (B) Dendrogram representing amino acid
sequence similarity among prokineticins receptors and chemokine
receptors.
Trang 4macrophages a predominance of PROKR1 transcripts
was found, and macrophage cells extracted from
PRO-KR1 knockout mice were unable to respond to
PROK2 [29]
In humans, it has not yet been determined which
receptor is essential for the immunoactivities linked to
PROK1 or PROK2 Future directions for research
could come from the PROKR knockout mice that
have been recently generated Indeed, while
PRO-KR1) ⁄ ) mice have been obtained at the expected
Mendelian rate without critical abnormalities, > 50%
of PROKR2) ⁄ ) mice died at an early neonatal stage
and the surviving mice presented abnormalities similar
to Kallmann syndrome [31] Challenging the
PRO-KR1) ⁄ )and PROKR2) ⁄ )mice with various pathogens
could be a very informative model for studying the
role of prokineticin receptors in the immune system
Regulation
Very little is known about the regulation of prokineticin
and prokineticin receptors within immune cells
However, very recently PROK2 was shown to be
posi-tively regulated in CD11b+Gr1+ myeloid cells
(con-sisting mainly of neutrophils and cells of the
macrophage lineage), specifically by granulocyte
colony-stimulating factor and not by any other cytokine
tested [interleukin (IL)-4, IL-10, IL-13, monocyte
chemotactic protein-1, macrophage inflammatory
protein (MIP)-1a, MIP-1b, MIP-2, interferon-c,
kerati-nocyte-derived chemokine, fibroblast growth factor,
vascular endothelial factor, PROK2,
granulocyte–mac-rophage colony-stimulating growth factor (GM-CSF),
granulocyte colony-stimulating factor, tumor necrosis
factor-a (TNF-a), stromal cell-derived factor 1a and
transforming growth factor-b] [30] Furthermore, we
evaluated if the expression levels of PROK2 and
PROK1 could be regulated according to the
differentia-tion state of monocytic cells To achieve this we
com-pared the expression of PROK1 and PROK2 in
monocytes and monocyte-derived macrophages, in
undifferentiated and differentiated THP1 cells, and in
undifferentiated and differentiated U937 cells Our
results showed that PROK1 was undetectable in all
samples measured; however, PROK2 was highly
expressed in all cells in the undifferentiated state and
showed a large decrease in cells in the differentiated
state (data not shown)
For the regulation of PROKR1 and PROKR2 in
myeloid cells there is still much to be learned However,
we recently showed, by flow cytometry, that receptors
PROKR1 and PROKR2 were present on the surface of
monocytes, but that their expression was almost absent
on the same monocytes derived into macrophages by GM-CSF or into dendritic cells by GM-CSF + IL-4 (J Monnier, V Quillien, C Piquet-Pellorce, C Leberre,
L Preisser, H Gascan & M Samson, unpublished data) Altogether, these data suggest that the differenti-ation status of monocytic cells may have an impact
on the regulation of expression of prokineticin and prokineticin receptors
Functions of prokineticins and prokineticin receptors in the immune system
Prokineticin receptor signaling in immune cells The affinity of prokineticins for their receptors are in a similar range, with PROK2 showing a moderately higher affinity for both receptors: the Kd(nm) values for PROK1 and PROK2 binding to PROKR1 are 12.3 ± 4.2 and 1.4 ± 0.5, respectively, and the Kd(nm) values for PROK1 and PROK2 binding to PROKR2 are 1.8 ± 0.1 and 2.0 ± 0.7, respectively [9,32–34] Based on the literature it seems that intracellular calcium mobilization and Gq protein activation is one
of the major signaling mechanisms of prokineticin receptor activation [33–37] However, other studies have shown that prokineticin receptors can also couple
to Gi and Gs [26,32,33] Only a few reports have studied the prokineticin signaling mechanisms in immune cells It has been shown that human mono-cytes exposed to PROK2 induced extracellular signal-regulated kinase phosphorylation that was abolished
by pertussis toxin, suggesting involvement of the Gi protein signaling pathway [26] Interestingly, in mouse macrophages, it seems that pertussis toxin was unable
to block the actions of PROK2, but rather inhibition
of the Gq protein pathway blocked the secretion of cytokines mediated by PROK2 [29] Recently, we tested the effect of inhibitors of Gi protein (pertussis toxin) and calcium [using the intracellular calcium chelator 1, 2-bis (2-aminophenoxy) ethane-N, N, N’, N’-tetraacetic acid (BAPTA)] on human monocytes for their ability to block PROK1-mediated CXCL8 secretion Our results show that PROK1-mediated CXCL8 monocyte production was sensitive to pertussis toxin and BAPTA (J Monnier, V Quillien, C Piquet-Pellorce, C Leberre, L Preisser, H Gascan &
M Samson, unpublished data) Taken altogether, the results suggest that multiple pathways are involved in prokineticin signaling in monocytes, and that there might be some species-to-species variation
Furthermore, another molecular mechanism that could influence signaling is GPCR dimerization
Trang 5Indeed, it is now well described for chemokine
receptors such as CCR2 to CCR5 or CXCR4 to
CCR2 that dimerization can modulate signaling by
negative or positive binding cooperativity [38] Thus, it
would be very informative to determine if prokineticin
receptors can homodimerize or heterodimerize, and
how this would influence signaling
Hematopoietic activity of prokineticins
Identification that a prokineticin-like peptide
(Astaki-ne) induced a strong hematopoietic response in vivo, as
well as in vitro growth and differentiation of
hemato-poietic cells in invertebrates (shrimp and in crayfish),
suggests a primitive role for prokineticins as
hemato-poietic cytokines (Table 1) [1] In vertebrates, the
sys-temic expression of PROK1 or PROK2 by injection of
adenovirus into nude mice resulted in a potent
hematopoietic response Indeed, the total leukocyte,
neutrophil and monocyte count was increased, and
the mouse spleen was enlarged as a result of the large
number of immune cells produced (Table 1) [26]
Migration
In addition to their hematopoietic properties, PROK1
and PROK2 were also shown to be potent
chemoattrac-tants for human monocytes (Table 1) Indeed,
migra-tion of monocytes to prokineticins was observed at
concentrations as low as 10)8m[26], and mouse
macro-phages migrated in response to even lower concentra-tions of PROK2 (10)12m) [29] This is another property that prokineticins share with chemokines, which are first and foremost characterized by their ability to induce the migration of immune cells at very low con-centrations
Differentiation PROK1 has been shown to induce the differentiation
of both human and mouse bone marrow cells into the monocyte⁄ macrophage lineage (Table 1) In vitro, human and mouse hematopoietic stem cells treated with either PROK1 or PROK2 showed an increase in the number of granulocytic and monocytic colony-forming units [26] This was further observed in another study where human and mouse CD34+ cells showed a decrease in expression of CD34 and increase
in expression of CD14 after treatment with PROK1
As well as inducing monocyte survival for 7 days, PROK1 differentiated monocytes into macrophage-like cells, as observed by the morphological changes induced in monocytes and the down-regulation of sur-face expression of B7-1, CD14, CXCR4 and CCR5 [24]
Cytokine and chemokine induction
By observing the cytokine signature induced in mono-cyte⁄ macrophages by prokineticins, several studies
Table 1 Summary of the effects induced by prokineticins on blood cells.
1 Action of PKs on blood cells
Hematopoietic response › Monocyte + neutrophil count
› CFU-G and CFU-M (Lecouter et al [26])
› Monocyte + neutrophil count
› CFU-G and CFU-M (Lecouter et al [26])
› Hematopoiesis in vivo and
in vitro (Soderhall et al [1])
(Lecouter et al [26])
Monocytes (Lecouter et al [26]) Macrophages (Martucci et al [29]) Survival ⁄ differentiation › Monocyte survival
› Macrophage differentiation (Dorsch et al [24]; Lecouter et al [26])
› Monocyte survival (Lecouter et al [26]) Morphological changes › B7-2, fl B7-1, CCR5, CXCR4, CD14
(Dorsch et al [24])
2 Monocyte/macrophage cytokine production
(Monnier et al [25]; Kisliouk et al [27])
(Monnier et al [25])
› IL-1, fl IL-10 (Martucci et al [29])
(Martucci et al [29)]
7 days with PK1, then
24 h with LPS
› TNF-a, IL-12, fl IL-10 (Dorsch et al [24])
Trang 6have demonstrated that prokineticins function as
pro-inflammatory mediators (Table 1) [24,27,29] Indeed,
monocytes treated for 7 days with PROK1 are primed
to release TNF-a and IL-12, and to decrease IL-10
after treatment with lipopolysaccharide (LPS) [24]
In mouse macrophages, PROK2, in conjunction with
LPS, induced IL-1 and decreased IL-10 production,
and co-stimulation of PROK2 with LPS plus
inter-feron-c induced IL-12 [29] Interestingly, those two
studies only demonstrated an indirect response to
PROK1 or PROK2 in differentiated monocytes
However, other reports using fresh monocytes were
able to show a direct response for cytokine
produc-tion by prokineticins In bovine monocytes,
incuba-tion with either PROK1 or PROK2 for 48 h
increased the levels of integrin b2, elevated the
num-ber of adherent cells, and stimulated TNF-a mRNA
expression, implying that prokineticins participate in
the activation of bovine monocytes [27] We observed,
in human monocytes treated with 1 lgÆmL)1 of
PROK1 for 8 h just after plating, that IL-1b and
TNF-a transcripts were strongly induced (data not
shown) Furthermore, we observed that monocytes
treated with PROK1 for 24 h secreted the chemokines
CXCL1, CXCL8 and CCL4 In addition,
costimula-tion with LPS and PROK1 showed synergy for
CCL18 and CCL20 production Finally, we observed
that CXCL1 and CXCL8 secretion after PROK1
induction is only observed in monocytes and not in
monocyte-derived macrophages or dendritic cells,
probably because of the decrease of receptors in
macrophages and dendritic cells described previously
(J Monnier, V Quillien, C Piquet-Pellorce, C
Leb-erre, L Preisser, H Gascan & M Samson, unpublished
data) Taken together it seems that, in vitro, the
differentiation state of monocytes has an impact on
the ability of prokineticins alone to induce
chemo-kines and cytochemo-kines
Conclusion/perspectives
In conclusion, this review attempted to present the
many similar traits between prokineticins and
cyto-kines Indeed, prokineticins show greater similarity to
the chemokine family than to members of the
inter-leukin family They share with chemokines many
similar aspects: they are small secreted peptides, they
are highly basic and bind heparane sulfates, they both
contain cysteine residues, their N terminus is essential
for proper signaling, they signal through GPCRs, they
show multiple receptors with ligand cross-reactivity
and they are potent chemoattractants Furthermore,
prokineticins also induce survival, differentiation and
activation of the granulocytic and monocytic lineages, and they can be considered as pleiotropic chemokine-like cytokines However, there is still much to be understood on how prokineticins modulate the innate and adaptive immune systems
Acknowledgements
Justin Monnier was supported by a PhD fellowship from the Region Bretagne Michel Samson was supported by the Institut National de la Sante´ et de
la Recherche Me´dicale (INSERM)
References
1 Soderhall I, Kim YA, Jiravanichpaisal P, Lee SY & Soderhall K (2005) An ancient role for a prokineticin domain in invertebrate hematopoiesis J Immunol 174, 6153–6160
2 Negri L, Lattanzi R, Giannini E & Melchiorri P (2007) Bv8⁄ Prokineticin proteins and their receptors Life Sci
81, 1103–1116
3 Mollay C, Wechselberger C, Mignogna G, Negri L, Melchiorri P, Barra D & Kreil G (1999) Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats Eur J Pharmacol
374, 189–196
4 Li M, Bullock CM, Knauer DJ, Ehlert FJ & Zhou QY (2001) Identification of two prokineticin cDNAs: recombinant proteins potently contract gastrointestinal smooth muscle Mol Pharmacol 59, 692–698
5 LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller GA et al (2001) Identification of an angiogenic mitogen selective for endocrine gland endothelium Nature 412, 877–884
6 Pitteloud N, Zhang C, Pignatelli D, Li JD, Raivio T, Cole LW, Plummer L, Jacobson-Dickman EE, Mellon
PL, Zhou QY et al (2007) From the cover: loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogo-nadotropic hypogonadism Proc Natl Acad Sci U S A
104, 17447–17452
7 Zhou QY & Cheng MY (2005) Prokineticin 2 and circa-dian clock output Febs J 272, 5703–5709
8 Zhou QY (2006) The prokineticins: a novel pair of regulatory peptides Mol Interv 6, 330–338
9 Maldonado-Perez D, Evans J, Denison F, Millar RP & Jabbour HN (2007) Potential roles of the prokineticins
in reproduction Trends Endocrinol Metab 18, 66–72
10 LeCouter J & Ferrara N (2003) EG-VEGF and Bv8 a novel family of tissue-selective mediators of angiogene-sis, endothelial phenotype, and function Trends Cardio-vasc Med 13, 276–282
Trang 711 Kaser A, Winklmayr M, Lepperdinger G & Kreil G
(2003) The AVIT protein family Secreted cysteine-rich
vertebrate proteins with diverse functions EMBO Rep
4, 469–473
12 Leroy C, Fouveaut C, Leclercq S, Jacquemont S,
Boul-lay HD, Lespinasse J, Delpech M, Dupont JM,
Harde-lin JP & Dode C 2008 Biallelic mutations in the
prokineticin-2 gene in two sporadic cases of Kallmann
syndrome Eur J Hum Genet 16, 856–858
13 Dode C, Teixeira L, Levilliers J, Fouveaut C, Bouchard
P, Kottler ML, Lespinasse J, Lienhardt-Roussie A,
Mathieu M, Moerman A et al (2006) Kallmann
syn-drome: mutations in the genes encoding prokineticin-2
and prokineticin receptor-2 PLoS Genet 2, e175
14 LeCouter J, Lin R, Tejada M, Frantz G, Peale F,
Hillan KJ & Ferrara N (2003) The
endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis
in the testis: localization of Bv8 receptors to endothelial
cells Proc Natl Acad Sci U S A 100, 2685–2690
15 Bieche I, Chavey C, Andrieu C, Busson M, Vacher S,
Le Corre L, Guinebretiere JM, Burlinchon S, Lidereau
R & Lazennec G (2007) CXC chemokines located in
the 4q21 region are up-regulated in breast cancer
Endocr Relat Cancer 14, 1039–1052
16 Bullock CM, Li JD & Zhou QY (2004) Structural
determinants required for the bioactivities of
prokinetic-ins and identification of prokineticin receptor
antago-nists Mol Pharmacol 65, 582–588
17 Wolf M, Albrecht S & Marki C (2007) Proteolytic
pro-cessing of chemokines: implications in physiological and
pathological conditions Int J Biochem Cell Biol 40,
1185–1198
18 Parish CR (2006) The role of heparan sulphate in
inflammation Nat Rev Immunol 6, 633–643
19 Chevenet F, Brun C, Banuls AL, Jacq B & Christen R
(2006) TreeDyn: towards dynamic graphics and
annota-tions for analyses of trees BMC Bioinformatics 7, 439
20 Guindon S & Gascuel O (2003) A simple, fast, and
accurate algorithm to estimate large phylogenies by
maximum likelihood Syst Biol 52, 696–704
21 Anisimova M & Gascuel O (2006) Approximate
likeli-hood-ratio test for branches: a fast, accurate, and
powerful alternative Syst Biol 55, 539–552
22 Thompson JD, Higgins DG & Gibson TJ (1994)
CLUSTAL W: improving the sensitivity of progressive
multiple sequence alignment through sequence
weight-ing, position-specific gap penalties and weight matrix
choice Nucleic Acids Res 22, 4673–4680
23 Samson M, Soularue P, Vassart G & Parmentier M
(1996) The genes encoding the human CC-chemokine
receptors CC-CKR1 to CC-CKR5
(CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of
chromosome 3 Genomics 36, 522–526
24 Dorsch M, Qiu Y, Soler D, Frank N, Duong T,
Goodearl A, O’Neil S, Lora J & Fraser CC 2005
PK1⁄ EG-VEGF induces monocyte differentiation and activation J Leukoc Biol 78, 426–434
25 Monnier J, Piquet-Pellorce C, Feige JJ, Musso O, Clement B, Turlin B, Theret N & Samson M (2008) Prokineticin 2⁄ Bv8 is expressed in Kupffer cells in liver and is down regulated in human hepatocellular carcinoma World J Gastroenterol 14, 1182–1191
26 LeCouter J, Zlot C, Tejada M, Peale F & Ferrara N (2004) Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization Proc Natl Acad Sci
U S A 101, 16813–16818
27 Kisliouk T, Friedman A, Klipper E, Zhou QY, Schams
D, Alfaidy N & Meidan R (2007) Expression pattern
of prokineticin 1 and its receptors in bovine ovaries during the estrous cycle: involvement in corpus luteum regression and follicular atresia Biol Reprod 76, 749–758
28 Zhang L, Yang N, Conejo-Garcia JR, Katsaros D, Mohamed-Hadley A, Fracchioli S, Schlienger K, Toll
A, Levine B, Rubin SC et al (2003) Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma Clin Cancer Res 9, 264–272
29 Martucci C, Franchi S, Giannini E, Tian H, Melchiorri
P, Negri L & Sacerdote P (2006) Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages
Br J Pharmacol 147, 225–234
30 Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N et al (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis Nature 450, 825–831
31 Matsumoto S, Yamazaki C, Masumoto KH, Nagano
M, Naito M, Soga T, Hiyama H, Matsumoto M, Takasaki J, Kamohara M et al (2006) Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2 Proc Natl Acad Sci U S A 103, 4140–4145
32 Chen J, Kuei C, Sutton S, Wilson S, Yu J, Kamme F, Mazur C, Lovenberg T & Liu C (2005) Identification and pharmacological characterization of prokineticin 2 beta as a selective ligand for prokineticin receptor 1 Mol Pharmacol 67, 2070–2076
33 Lin DC, Bullock CM, Ehlert FJ, Chen JL, Tian H & Zhou QY (2002) Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins⁄ endocrine gland vascular endothelial growth factor J Biol Chem
277, 19276–19280
34 Soga T, Matsumoto S, Oda T, Saito T, Hiyama H, Takasaki J, Kamohara M, Ohishi T, Matsushime H & Furuichi K (2002) Molecular cloning and characteri-zation of prokineticin receptors Biochim Biophys Acta
1579, 173–179
Trang 835 Masuda Y, Takatsu Y, Terao Y, Kumano S, Ishibashi
Y, Suenaga M, Abe M, Fukusumi S, Watanabe T,
Shintani Y et al (2002) Isolation and identification of
EG-VEGF⁄ prokineticins as cognate ligands for two
orphan G-protein-coupled receptors Biochem Biophys
Res Commun 293, 396–402
36 Negri L, Lattanzi R, Giannini E, Metere A, Colucci M,
Barra D, Kreil G & Melchiorri P (2002) Nociceptive
sensitization by the secretory protein Bv8 Br J
Pharma-col 137, 1147–1154
37 Vellani V, Colucci M, Lattanzi R, Giannini E, Negri
L, Melchiorri P & McNaughton PA (2006) Sensiti-zation of transient receptor potential vanilloid 1 by the prokineticin receptor agonist Bv8 J Neurosci 26, 5109– 5116
38 Springael JY, Urizar E & Parmentier M (2005) Dimerization of chemokine receptors and its functional consequences Cytokine Growth Factor Rev 16, 611– 623